Dynamic Technology Lab Private Ltd Raises Stock Holdings in Repligen Corporation $RGEN

Key Points

• Dynamic Technology Lab Private Ltd significantly increased its stake in Repligen Corporation by 233.6% during the first quarter, holding 9,208 shares valued at approximately $1.17 million.
• Several institutional investors have also raised their positions, with 97.64% of Repligen's stock owned by hedge funds and institutional investors.
• Repligen's stock has received multiple "overweight" ratings from analysts, with a consensus target price of $169.55 amid recent performance showing revenue growth of 14.8% year-over-year.

Dynamic Technology Lab Private Ltd increased its holdings in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 233.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,208 shares of the biotechnology company's stock after purchasing an additional 6,448 shares during the period. Dynamic Technology Lab Private Ltd's holdings in Repligen were worth $1,172,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in RGEN. Raiffeisen Bank International AG acquired a new stake in Repligen during the fourth quarter worth approximately $29,000. Twin Tree Management LP acquired a new stake in Repligen in the first quarter worth $29,000. Signaturefd LLC grew its holdings in Repligen by 65.3% in the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company's stock worth $41,000 after purchasing an additional 128 shares during the period. Center for Financial Planning Inc. grew its holdings in Repligen by 110.3% in the first quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company's stock worth $47,000 after purchasing an additional 193 shares during the period. Finally, UMB Bank n.a. grew its holdings in Repligen by 99.4% in the first quarter. UMB Bank n.a. now owns 666 shares of the biotechnology company's stock worth $85,000 after purchasing an additional 332 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.

Insider Activity at Repligen

In other Repligen news, Director Martin D. Madaus bought 1,800 shares of Repligen stock in a transaction that occurred on Friday, August 8th. The stock was acquired at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the completion of the transaction, the director directly owned 1,800 shares in the company, valued at $201,834. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. 1.20% of the stock is owned by insiders.

Repligen Stock Up 1.3%

Shares of NASDAQ:RGEN traded up $1.54 during mid-day trading on Wednesday, hitting $120.23. 986,487 shares of the company traded hands, compared to its average volume of 663,220. The stock has a market cap of $6.76 billion, a P/E ratio of -480.90, a P/E/G ratio of 2.18 and a beta of 1.07. The company has a current ratio of 8.59, a quick ratio of 7.32 and a debt-to-equity ratio of 0.26. Repligen Corporation has a 12-month low of $102.96 and a 12-month high of $182.52. The stock has a 50-day moving average price of $121.16 and a two-hundred day moving average price of $128.66.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The business had revenue of $182.37 million for the quarter, compared to the consensus estimate of $174.62 million. During the same quarter last year, the business posted $0.40 earnings per share. The business's revenue was up 14.8% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. On average, equities research analysts forecast that Repligen Corporation will post 1.72 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have commented on RGEN shares. Stephens raised Repligen to an "overweight" rating and set a $160.00 price objective for the company in a research note on Tuesday, July 22nd. Wells Fargo & Company reduced their price objective on Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a research note on Wednesday, July 30th. HC Wainwright reissued a "buy" rating and issued a $180.00 price objective on shares of Repligen in a research note on Wednesday, September 3rd. Wall Street Zen lowered shares of Repligen from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $205.00 price objective on shares of Repligen in a research note on Tuesday, September 2nd. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, Repligen has an average rating of "Moderate Buy" and a consensus target price of $169.55.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.